IRIS
SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.922
EU - Europa 1.311
AS - Asia 1.265
SA - Sud America 408
AF - Africa 92
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.880
SG - Singapore 421
BR - Brasile 320
VN - Vietnam 274
RU - Federazione Russa 232
CN - Cina 202
UA - Ucraina 191
IT - Italia 175
SE - Svezia 141
DE - Germania 131
IE - Irlanda 123
TR - Turchia 108
HK - Hong Kong 79
FI - Finlandia 77
FR - Francia 73
DK - Danimarca 68
GB - Regno Unito 52
CI - Costa d'Avorio 40
IN - India 39
KR - Corea 38
BD - Bangladesh 24
AR - Argentina 21
JP - Giappone 21
MA - Marocco 21
MX - Messico 18
CO - Colombia 17
CA - Canada 16
IQ - Iraq 15
ZA - Sudafrica 14
EC - Ecuador 12
NL - Olanda 12
CL - Cile 9
PL - Polonia 9
VE - Venezuela 9
ID - Indonesia 8
ES - Italia 7
PY - Paraguay 7
UY - Uruguay 7
BE - Belgio 5
KE - Kenya 5
PE - Perù 5
PK - Pakistan 5
UZ - Uzbekistan 5
CZ - Repubblica Ceca 4
EU - Europa 4
MY - Malesia 4
PH - Filippine 4
SA - Arabia Saudita 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
RS - Serbia 3
SC - Seychelles 3
AT - Austria 2
AZ - Azerbaigian 2
CR - Costa Rica 2
DZ - Algeria 2
HN - Honduras 2
LT - Lituania 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GT - Guatemala 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LB - Libano 1
MM - Myanmar 1
MT - Malta 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
TH - Thailandia 1
TW - Taiwan 1
Totale 6.002
Salva come PNG Salva come JPEG
Città #
Ashburn 564
Singapore 291
Fairfield 210
Jacksonville 209
Chandler 199
Dublin 121
San Jose 121
Wilmington 120
Dallas 117
Des Moines 100
Boardman 96
Woodbridge 95
New York 86
Ho Chi Minh City 81
Seattle 77
Hong Kong 76
Houston 71
Hanoi 69
The Dalles 67
Beijing 58
Cambridge 50
Centro 49
Lawrence 47
Los Angeles 47
Princeton 47
San Mateo 43
Ann Arbor 42
Lauterbourg 42
Moscow 41
Abidjan 39
Munich 34
São Paulo 28
Turin 28
Helsinki 23
San Diego 22
London 19
Turku 19
Buffalo 16
Tokyo 15
Hefei 14
Frankfurt am Main 13
Orem 13
Chicago 12
Porto Alegre 12
Chennai 11
Da Nang 11
Washington 11
Haiphong 10
Johannesburg 9
Pune 9
Rio de Janeiro 9
Columbus 8
Curitiba 8
Denver 8
Paris 8
Santa Clara 8
Atlanta 7
Guayaquil 7
Montevideo 7
Rome 7
Warsaw 7
Amsterdam 6
Belo Horizonte 6
Brasília 6
Kilburn 6
Mumbai 6
Norwalk 6
Shanghai 6
Ancona 5
Bogotá 5
Bến Tre 5
Campinas 5
Can Tho 5
Council Bluffs 5
Fortaleza 5
Montreal 5
Salvador 5
Santiago 5
Stockholm 5
Tashkent 5
Thái Nguyên 5
Toronto 5
Wuhan 5
Brussels 4
Cagliari 4
Dhaka 4
Goiânia 4
Izmir 4
Manchester 4
Medellín 4
Nairobi 4
Olomouc 4
Petrópolis 4
Phoenix 4
San Francisco 4
Thái Bình 4
Vĩnh Long 4
Ankara 3
Brooklyn 3
Cape Town 3
Totale 3.870
Salva come PNG Salva come JPEG
Nome #
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 193
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 187
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 174
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 173
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 169
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 164
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 160
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 152
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 152
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 149
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 147
BRAF-mutant colorectal cancer, a different breed evolving 147
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 143
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 142
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 140
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 139
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 138
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 134
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 134
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 133
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 131
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 128
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 127
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 127
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 126
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 123
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 123
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 123
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 122
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 120
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 115
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 113
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 112
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 110
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 109
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 108
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 107
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 105
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 101
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 100
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 99
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 99
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 98
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 98
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 85
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 83
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res. 2013 Oct;33(10):4611-7 73
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 39
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 29
Totale 6.103
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.624
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.624
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 78 52 46
2021/2022364 36 66 10 2 1 28 15 21 24 62 42 57
2022/2023745 52 93 51 42 37 165 0 38 177 5 75 10
2023/2024408 66 8 37 42 62 114 7 12 0 7 10 43
2024/2025866 122 67 15 13 39 41 104 34 162 66 99 104
2025/20262.272 168 211 154 261 300 161 406 245 195 171 0 0
Totale 6.103